These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2134707)

  • 1. Study on thermostabilizers for trivalent oral poliomyelitis vaccine.
    Leal ML; Lopes FJ; Carvalho MH; Moura HA; Soares SA
    Mem Inst Oswaldo Cruz; 1990; 85(3):329-38. PubMed ID: 2134707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thermostability of poliovirus and measles vaccines.
    Melnick JL
    Dev Biol Stand; 1996; 87():155-60. PubMed ID: 8854012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The replacement of water with deuterium oxide significantly improves the thermal stability of the oral poliovirus vaccine.
    Crainic R; Wu R; Otelea D; Georgescu MM; Delpeyroux F; Guillot S; Balanant J; Tardy-Panit M
    Dev Biol Stand; 1996; 87():161-6. PubMed ID: 8854013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRIVALENT ORAL POLIO VACCINE: CLINICAL TRIAL OF A NEW FORMULATION.
    BURKE DM; GOW RC
    Clin Pediatr (Phila); 1963 Sep; 2():517-20. PubMed ID: 14047178
    [No Abstract]   [Full Text] [Related]  

  • 5. The thermostability of vaccines. Technologies for improving the thermostability of the oral poliovirus vaccine.
    Lemon SM; Milstien JB
    Int J Technol Assess Health Care; 1994; 10(1):177-84. PubMed ID: 8157450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stabilisation of poliovirus with pirodavir.
    Rombaut B; Andries K; Boeyé A
    Dev Biol Stand; 1996; 87():173-80. PubMed ID: 8854015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutathione is a highly efficient thermostabilizer of poliovirus Sabin strains.
    Abdelnabi R; Delang L; Neyts J
    Vaccine; 2017 Mar; 35(10):1370-1372. PubMed ID: 28189401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elucidating mechanisms of thermostabilization of poliovirus by D2O and MgCl2.
    Chen CH; Wu R; Roth LG; Guillot S; Crainic R
    Arch Biochem Biophys; 1997 Jun; 342(1):108-16. PubMed ID: 9185619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capsid and RNA stabilisation of the oral polio vaccine.
    Verheyden B; Andries K; Rombaut B
    Vaccine; 2001 Feb; 19(15-16):1899-905. PubMed ID: 11228359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of formulation on spray dried Sabin inactivated polio vaccine.
    Kanojia G; Ten Have R; Brugmans D; Soema PC; Frijlink HW; Amorij JP; Kersten G
    Eur J Pharm Biopharm; 2018 Aug; 129():21-29. PubMed ID: 29787800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Thermostability and immunogenicity of trivalent oral poliovirus vaccine produced by different countries].
    Kong J
    Zhonghua Liu Xing Bing Xue Za Zhi; 1993 Jun; 14(3):151-4. PubMed ID: 8221837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stabilization of the attenuated poliovirus type 3 vaccine strain by sucrose.
    Srivastava AK
    Acta Virol; 1989 Mar; 33(2):188-90. PubMed ID: 2569817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monovalent type 1 oral poliovirus vaccine in newborns.
    el-Sayed N; el-Gamal Y; Abbassy AA; Seoud I; Salama M; Kandeel A; Hossny E; Shawky A; Hussein HA; Pallansch MA; van der Avoort HG; Burton AH; Sreevatsava M; Malankar P; Wahdan MH; Sutter RW
    N Engl J Med; 2008 Oct; 359(16):1655-65. PubMed ID: 18923170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.
    Thompson KM; Duintjer Tebbens RJ
    BMC Infect Dis; 2015 Sep; 15():374. PubMed ID: 26381878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stabilising oral poliovaccine at high ambient temperatures.
    Newman JF; Tirrell S; Ullman C; Piatti PG; Brown F
    Dev Biol Stand; 1996; 87():103-11. PubMed ID: 8854007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies.
    Mas Lago P; Ramon Bravo J; Andrus JK; Comellas MM; Galindo MA; de Quadros CA; Bell E
    Bull World Health Organ; 1994; 72(2):221-5. PubMed ID: 8205641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Freeze-Drying of L-Arginine/Sucrose-Based Protein Formulations, Part 2: Optimization of Formulation Design and Freeze-Drying Process Conditions for an L-Arginine Chloride-Based Protein Formulation System.
    Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
    J Pharm Sci; 2015 Dec; 104(12):4241-4256. PubMed ID: 26422647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory considerations for new stabilised poliovaccines.
    Milstien JB; Lemon S
    Dev Biol Stand; 1996; 87():181-9. PubMed ID: 8854016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heat stability of the lyophilized Sabin poliovaccine.
    Shiomi H; Urasawa T; Urasawa S
    Jpn J Infect Dis; 2003 Apr; 56(2):70-2. PubMed ID: 12824691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.